EE370 Cost-Effectiveness Analysis of Pembrolizumab as Adjuvant Treatment for Resected Stage IIB/IIC Melanoma in Greece

Abstract

Authors

N. Yfantopoulos F. Spanoudi A. Draganigos A. Skroumpelos A. Karokis

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×